Cognitive Function in a Randomized Trial of Evolocumab

To the Editor: In the article regarding cognitive function in patients receiving the proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab, Giugliano et al. (Aug. 17 issue) 1 report that evolocumab does not affect neurocognition, even in patients who attained very low levels of...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 377; no. 20; pp. 1996 - 1997
Main Authors Calabrò, Paolo, Gragnano, Felice, Pirro, Matteo, Giugliano, Robert P, Sabatine, Marc S, Ott, Brian R
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 16.11.2017
Subjects
Antibodies, Monoclonal
Cholesterol, LDL
Cognition
Humans
Hypercholesterolemia
Online AccessGet full text

Cover

More Information
Summary:To the Editor: In the article regarding cognitive function in patients receiving the proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab, Giugliano et al. (Aug. 17 issue) 1 report that evolocumab does not affect neurocognition, even in patients who attained very low levels of low-density lipoprotein (LDL) cholesterol. In the EBBINGHAUS trial (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects), Giugliano et al. prospectively assessed cognitive function across a wide range of domains, including memory and attention. However, no test was performed to evaluate depressive symptoms specifically. Depression negatively affects performance on cognitive tests and may . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1712102